EMBL sells ViraTherapeutics to trade for €210m

The acquirer signed a collaboration and option agreement with ViraTherapeutics in August 2016, after participating in its series-A in June 2015.

After the acquisition, ViraTherapeutics will operate in Innsbruck as a distinct unit of Boehringer Ingelheim's Discovery Research organisation.

Previous funding
ViraTherapeutics received pre-seed funding from Startup.Tirol (previously Center for Academic Spin-offs Tyrol), and from Austria Wirtschaftsservice (AWS – the Austrian Government Promotional Bank).

Boehringer Ingelheim co-led ViraTherapeutics' series-A round with EMBL via its corporate venturing arm Boehringer Ingelheim Venture Fund. EMBL drew capital from its €50m vehicle EMBL Technology Fund II to support the €3.6m funding round.

Company
Founded in 2013 as a spinout from the Medical University of Innsbruck, ViraTherapeutics develops oncolytic cancer vaccines based on a chimeric virus. It currently employs 19 people.

People
EMBL Ventures – Jan Adams (managing partner).
ViraTherapeutics – Heinz Schwer (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• Venture
• Trade sale
• Austria